Skip to main content

Table 2 Relationships between the expression of ANXA2, HE4 and clinicopathological parameters of 84 endometrial carcinoma patients

From: Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma

Parameters Cases ANXA2 HE4
Positive exp. (%) P-value High exp. (%) P-value Positive exp. (%) P-value High exp. (%) P-value
Age at diagnosis
  < 59 42 39(92.9 %) p > 0.05 26(61.9 %) p > 0.05 36(85.7 %) p > 0.05 18(42.9 %) p > 0.05
  ≥ 59 42 41(97.6 %) 29(69.0 %) 36(85.7 %) 20(47.6 %)
FIGO stage
 I 53 49(92.5 %) p > 0.05 29(54.7 %) p I-II/III-IV  = 0.001 45(84.9 %) p > 0.05 20(37.7 %) p I-II/III-IV  = 0.013
 II 7 7(100 %) 4(57.1 %) 5(71.4 %) 2(28.6 %)
 III 21 21(100 %) 19(90.5 %) 19(90.5 %) 13(61.9 %)
 IV 3 3(100 %) 3(100 %) 3(100.0 %) 3(100 %)
Pathologic type
 Endometiod 39 35(89.7 %) p > 0.05 23(59.0 %) p > 0.05 34(87.2 %) p > 0.05 18(46.2 %) p > 0.05
 Serous 19 19(100 %) 13(68.4 %) 15(78.9 %) 6(31.6 %)
 Clear cell 17 17(100 %) 12(70.6 %) 16(94.1 %) 8(47.1 %)
 Othersa 9 9(100 %) 7(77.8 %) 7(77.8 %) 6(66.7 %)
Differentiation
 Well 17 14(82.4 %) p well/poor  = 0.020 4(23.5 %) p well/mod. = 0.003 13(76.5 %) p > 0.05 3(17.6 %) p well/mod. = 0.009
 Moderate 24 23(95.8 %) 17(70.8 %) p well/poor  < 0.001 22(91.7 %) 14(58.3 %) p well/poor = 0.026
 Poor 43 43(100 %) 34(79.1 %) 37(86.0 %) 21(48.8 %)
ERb
 - 45 44(97.8 %) p > 0.05 33(73.3 %) p −/+ = 0.031 40(88.9 %) p > 0.05 21(46.7 %) p > 0.05
 + 27 24(88.9 %) 13(48.1 %) 22(81.5 %) 11(40.7 %)
 Unknown 12 12(100 %) 9(75.0 %) 10(83.3 %) 6(50.0 %)
PRc
 - 43 43(100 %) p −/+  = 0.023 33(76.7 %) p −/+ = 0.006 39(90.7 %) p > 0.05 21(48.8 %) p > 0.05
 + 29 25(86.2 %) 13(44.8 %) 24(82.8 %) 12(41.4 %)
 Unknown 12 12(100 %) 9(75.0 %) 9(75.0 %) 5(41.7 %)
Muscular invasion
  < 1/2 51 47(92.2 %) p > 0.05 28(54.9 %) p = 0.011 42(82.4 %) p > 0.05 17(33.3 %) p = 0.006
  ≥ 1/2 33 33(100 %) 27(81.8 %) 30(90.9 %) 21(63.6 %)
LN metastasisd
 - 50 48(96.0 %) p > 0.05 29(58.0 %) p −/+ = 0.003 44(88.0 %) p > 0.05 18(36.0 %) p −/+ = 0.016
 + 19 19(100 %) 18(94.7 %) 18(94.7 %) 13(68.4 %)
 Unknown 15 13(86.7 %) 8(53.3 %) 10(66.7 %) 7(46.7 %)
  1. a”Others” including 4 mucous carcinoma, 2 squamous carcinoma, 2 undifferentiated carcinoma, 1 small cell carcinoma
  2. b12 patients without ER detection
  3. c12 patients without PR detection
  4. d15 patients without lymphadenectomy
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us